These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 5568050)

  • 21. Oral anticoagulants and drug interactions.
    Ebert RV
    Arch Intern Med; 1968 Apr; 121(4):373-4. PubMed ID: 5645713
    [No Abstract]   [Full Text] [Related]  

  • 22. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
    Orstavik KH
    Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and clinical use of factor IX concentrate PPSB according to Soulier.
    Haanen C; McShine RL; Kunst A
    Vox Sang; 1969 Apr; 16(4):398-411. PubMed ID: 5800593
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral anticoagulant therapy and international normalized ratios in swine.
    McGlasson DL; Brickey DA; Doe RH
    Lab Anim Sci; 1998 Aug; 48(4):371-3. PubMed ID: 10090045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation.
    Watzke HH; Forberg E; Svolba G; Jimenez-Boj E; Krinninger B
    Thromb Haemost; 2000 May; 83(5):661-5. PubMed ID: 10823258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticoagulant activity of Heraclenin.
    Mishra KC; Sharma RC; Sharma YN; Arora RB
    Indian J Physiol Pharmacol; 1969 Jul; 13(3):153-5. PubMed ID: 5362630
    [No Abstract]   [Full Text] [Related]  

  • 28. Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
    Bertina RM; van der Linden IK
    Thromb Haemost; 1982 Apr; 47(2):136-40. PubMed ID: 7101232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific coagulation factor adsorption as related to functional groups on surfaces.
    Oja PD; Holmes GW; Perkins HA; Love J
    J Biomed Mater Res; 1969 Mar; 3(1):165-74. PubMed ID: 5784962
    [No Abstract]   [Full Text] [Related]  

  • 30. Method of detection of deficiencies of hemophilia A (8) and B factor (IX).
    Norén I; Blombäck M
    Bibl Haematol; 1966; 26():94-9. PubMed ID: 5955573
    [No Abstract]   [Full Text] [Related]  

  • 31. Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: in vitro and in vivo evidence.
    Grundman C; Plesker R; Kusch M; Hanschmann KM; Eich S; Seitz R; König H
    Thromb Haemost; 2005 Dec; 94(6):1338-9. PubMed ID: 16411418
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Substitution therapy with prothrombin complex concentrates in acquired coagulation disorders].
    Fischer M
    Wien Klin Wochenschr; 1983 Feb; 95(3):82-5. PubMed ID: 6858171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0.
    Denas G; Cucchini U; Iliceto S; Pengo V
    Thromb Haemost; 2009 Feb; 101(2):410-1. PubMed ID: 19190831
    [No Abstract]   [Full Text] [Related]  

  • 35. Management of oral anticoagulant treatment in patients with venous thromboembolism.
    Pengo V
    Semin Thromb Hemost; 2006 Nov; 32(8):781-6. PubMed ID: 17171590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
    Bertina RM; Van Der Linden IK
    J Lab Clin Med; 1982 Nov; 100(5):695-704. PubMed ID: 7130828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
    Yasaka M; Sakata T; Naritomi H; Minematsu K
    Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anticoagulant action of a new synthetic derivative of 4-hydroxycoumarin and antagonism by synthetic vitamin K1 in the rat].
    Thonnart N; Letist D; Reuse JJ
    C R Seances Soc Biol Fil; 1973; 167(6):1081-5. PubMed ID: 4803162
    [No Abstract]   [Full Text] [Related]  

  • 39. [The effect of plasma fraction I-O, ACC 76, PAMBA and haemarctin on the blood coagulation system of premature newborn infants].
    Rogner G
    Z Kinderheilkd; 1967; 101(3):230-41. PubMed ID: 5626847
    [No Abstract]   [Full Text] [Related]  

  • 40. Studies on 4-hydroxy-I-thiacoumarins: VI--anticoagulant activity and chemical structure in 4-hydroxy-I-thiacoumarins and related compounds.
    Jamkhandi PS; Rajagopal S; Sirsi M
    Indian J Exp Biol; 1968 Oct; 6(4):224-6. PubMed ID: 5720680
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.